GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Total Noninterest Expense

Xeris Biopharma Holdings (LTS:0A8E) Total Noninterest Expense


View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Total Noninterest Expense?

Total Noninterest Expense only applies to banks.


Xeris Biopharma Holdings Business Description

Traded in Other Exchanges
Address
1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.